The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InDeutsche Bank has upgraded Humana from Hold to Buy, significantly raising its price target from $235 to $441. Concurrently, the bank lowered its price target for J.M. Smucker to $95 from $97 while maintaining a Hold rating. Mizuho also adjusted its outlook on Humana, setting a new price target of $335 with a continued Outperform rating.
These adjustments reflect diverging sentiment between the managed healthcare and food processing sectors. While Humana benefits from a more optimistic valuation recovery, food processors like J.M. Smucker face a tighter growth outlook. Per market data, peer companies such as UnitedHealth (UNH) continue to show resilience, providing a broader context for the aggressive price target hike issued for Humana by Deutsche Bank analysts.
Investors are tracking current price levels following the U.S. Producer Price Index (PPI) release on May 13, 2026, which came in at 1.4%, significantly higher than the 0.5% forecast. Looking ahead, the market will focus on upcoming speeches from Federal Reserve officials to gauge how persistent inflation might impact consumer-facing stocks and healthcare costs.